中国组织工程研究 ›› 2023, Vol. 27 ›› Issue (15): 2395-2403.doi: 10.12307/2023.355
• 干细胞综述 stem cell review • 上一篇 下一篇
郑晓晗1,2,3,魏艳召1,2,3,黄 婷1,2,3,魏绪芳2,孙圣童2,王 埮1,赵振强1
收稿日期:
2022-04-21
接受日期:
2022-06-27
出版日期:
2023-05-28
发布日期:
2022-10-18
通讯作者:
赵振强,博士,主任医师,海南医学院第一附属医院神经内科,海南省海口市 570100
王埮,博士,主任医师,海南医学院第一附属医院神经内科,海南省海口市 570100
作者简介:
郑晓晗,女,1995年生,福建省福州市人,汉族,海南医学院在读硕士,主要从事干细胞移植与神经系统疾病的研究。
基金资助:
Zheng Xiaohan1, 2, 3, Wei Yanzhao1, 2, 3, Huang Ting1, 2, 3, Wei Xufang2, Sun Shengtong2, Wang Tan1, Zhao Zhenqiang1
Received:
2022-04-21
Accepted:
2022-06-27
Online:
2023-05-28
Published:
2022-10-18
Contact:
Zhao Zhenqiang, MD, Chief physician, Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou 570100, Hainan Province, China
Wang Tan, MD, Chief physician, Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou 570100, Hainan Province, China
About author:
Zheng Xiaohan, Master candidate, Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou 570100, Hainan Province, China; Hainan Medical University, Haikou 570100, Hainan Province, China; Hainan Provincial Key Laboratory of Tropical Brain Research and Translation, Haikou 570100, Hainan Province, China
Supported by:
摘要:
文题释义:
巨噬细胞迁移抑制因子:是由多种细胞类型产生的一种多功能细胞因子,影响多种生物过程的调节功能,如增殖、迁移、凋亡和细胞周期进程。
干细胞治疗:是把健康的干细胞移植到患者体内,以修复或替换受损细胞或组织,从而达到治愈的目的。
背景:干细胞是一种可以自我更新并且具有分化潜能的细胞,干细胞治疗是一种很有前景的治疗方法。巨噬细胞迁移抑制因子几乎在所有哺乳动物细胞中都有表达,对许多生理过程至关重要。现有研究证明,巨噬细胞迁移抑制因子在多种干细胞上表达并且调节多种干细胞的增殖、分化和迁移。
目的:描述巨噬细胞迁移抑制因子的基本特征并着重阐述巨噬细胞迁移抑制因子对于干细胞的作用及机制。
方法:在PubMed和中国知网数据库中检索近10年文献,英文检索词为“macrophage migration inhibitory factor,cancer stem cell,embryonic stem cell,neural stem cell,mesenchymal stem cell,endothelial progenitor cell,stem cell therapy,tissue engineering”,中文检索词为“巨噬细胞移动抑制因子、肿瘤干细胞、胚胎干细胞、神经干细胞、间充质干细胞、内皮祖细胞、干细胞治疗、组织工程”,经过文题、摘要的筛选,排除相关性差及陈旧和重复的文献,对最终符合标准的85篇文献进行综述。
结果与结论:①巨噬细胞迁移抑制因子蛋白由3个亚基构成,在细胞表面通过与受体CD74,CD44,CXCR2,CXCR4和CXCR7产生作用。巨噬细胞迁移抑制因子储存在细胞内,通过非经典途径分泌,多种因素能影响其表达以及分泌。②巨噬细胞迁移抑制因子通过不同的信号通路促进肿瘤干细胞的迁移、侵袭、转移、逃逸和致瘤性。③当前研究中,比较明确的是巨噬细胞迁移抑制因子促进小鼠胚胎干细胞的神经分化。④巨噬细胞迁移抑制因子通过多个信号通路促进神经干细胞的增殖和存活。⑤巨噬细胞迁移抑制因子作用于间充质干细胞能够抑制凋亡、促进存活、延缓衰老并增加间充质干细胞的旁分泌作用,除此之外,巨噬细胞迁移抑制因子也证明可以通过结合受体CD74抑制间充质干细胞的归巢。⑥多项研究证明巨噬细胞迁移抑制因子通过CXCR4受体激活下游信号通路促进内皮细胞的迁移以及血管重建。⑦巨噬细胞迁移抑制因子作用于肿瘤干细胞、胚胎干细胞、神经干细胞、间充质干细胞、内皮祖细胞,对它们的增殖、分化、迁移和凋亡等过程产生影响,但其中部分作用还存在争议,确切机制需要更进一步验证。
https://orcid.org/0000-0003-0249-2734 (郑晓晗)
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
中图分类号:
郑晓晗, 魏艳召, 黄 婷, 魏绪芳, 孙圣童, 王 埮, 赵振强. 巨噬细胞迁移抑制因子对干细胞的作用[J]. 中国组织工程研究, 2023, 27(15): 2395-2403.
Zheng Xiaohan, Wei Yanzhao, Huang Ting, Wei Xufang, Sun Shengtong, Wang Tan, Zhao Zhenqiang. Role of macrophage migration inhibitory factor for stem cells[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(15): 2395-2403.
[1] BALISTRERI CR, DE FALCO E, BORDIN A, et al. Stem cell therapy: old challenges and new solutions. Mol Biol Rep. 2020;47(4):3117-3131. [2] ALESSANDRINI M, PREYNAT-SEAUVE O, DE BRUIN K, et al. Stem cell therapy for neurological disorders. S Afr Med J. 2019;109(8b):70-77. [3] NAIR N, GONGORA E. Stem cell therapy in heart failure: where do we stand today? Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165489. [4] BUJKO K, KUCIA M, RATAJCZAK J, et al. Hematopoietic stem and progenitor cells (HSPCs). Adv Exp Med Biol. 2019;1201:49-77. [5] AL-GHADBAN S, ARTILES M, BUNNELL BA. Adipose stem cells in regenerative medicine: looking forward. Front Bioeng Biotechnol. 2021;9:837464. [6] KWON SG, KWON YW, LEE TW, et al. Recent advances in stem cell therapeutics and tissue engineering strategies. Biomater Res. 2018;22:36. [7] SUMAIYA K, LANGFORD D, NATARAJASEENIVASAN K, et al. Macrophage migration inhibitory factor (MIF): a multifaceted cytokine regulated by genetic and physiological strategies. Pharmacol Ther. 2022;233:108024. [8] JANKAUSKAS SS, WONG DWL, BUCALA R, et al. Evolving complexity of MIF signaling. Cell Signal. 2019;57:76-88. [9] OHTA S, MISAWA A, FUKAYA R, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. J Cell Sci. 2012;125(Pt 13):3210-3220. [10] BARRILLEAUX BL, PHINNEY DG, FISCHER-VALUCK BW, et al. Small-molecule antagonist of macrophage migration inhibitory factor enhances migratory response of mesenchymal stem cells to bronchial epithelial cells. Tissue Eng Part A. 2009;15(9):2335-2346. [11] BECKER-HERMAN S, ROZENBERG M, HILLEL-KARNIEL C, et al. CD74 is a regulator of hematopoietic stem cell maintenance. PLoS Biol. 2021;19(3):e3001121. [12] KARABOWICZ J, DLUGOSZ E, BASKA P, et al. Nematode orthologs of macrophage migration inhibitory factor (MIF) as modulators of the host immune response and potential therapeutic targets. Pathogens. 2022;11(2):258. [13] SUN HW, BERNHAGEN J, BUCALA R, et al. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A. 1996; 93(11):5191-5196. [14] BILSBORROW JB, DOHERTY E, TILSTAM PV, et al. Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus. Expert Opin Ther Targets. 2019;23(9):733-744. [15] SU H, NA N, ZHANG X, et al. The biological function and significance of CD74 in immune diseases. Inflamm Res. 2017;66(3):209-216. [16] PONTA H, SHERMAN L, HERRLICH PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4(1):33-45. [17] CHATTERJEE M, BORST O, WALKER B, et al. Macrophage migration inhibitory factor limits activation-induced apoptosis of platelets via CXCR7-dependent Akt signaling. Circ Res. 2014;115(11):939-949. [18] VAN DER VORST EP, DöRING Y, WEBER C. Chemokines and their receptors in Atherosclerosis. J Mol Med (Berl). 2015;93(9):963-971. [19] DAYAWANSA NH, GAO XM, WHITE DA, et al. Role of MIF in myocardial ischaemia and infarction: insight from recent clinical and experimental findings. Clin Sci (Lond). 2014;127(3):149-161. [20] GRIEB G, SIMONS D, ECKERT L, et al. Levels of macrophage migration inhibitory factor and glucocorticoids in chronic wound patients and their potential interactions with impaired wound endothelial progenitor cell migration. Wound Repair Regen. 2012;20(5):707-714. [21] SINITSKI D, KONTOS C, KRAMMER C, et al. Macrophage migration inhibitory factor (MIF)-based therapeutic concepts in atherosclerosis and inflammation. Thromb Haemost. 2019;119(4):553-566. [22] ALAMPOUR-RAJABI S, EL BOUNKARI O, ROT A, et al. MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis. FASEB J. 2015;29(11):4497-4511. [23] XIA W, XIE C, JIANG M, et al. Improved survival of mesenchymal stem cells by macrophage migration inhibitory factor. Mol Cell Biochem. 2015;404(1-2):11-24. [24] LIANG JN, ZOU X, FANG XH, et al. The Smad3-miR-29b/miR-29c axis mediates the protective effect of macrophage migration inhibitory factor against cardiac fibrosis. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2441-2450. [25] LEE J, LEE J, JUNG E, et al. Ultraviolet A regulates adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells via up-regulation of Kruppel-like factor 2. J Biol Chem. 2010;285(42):32647-32656. [26] MERK M, BAUGH J, ZIEROW S, et al. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol. 2009;182(11):6896-6906. [27] 黄琳,马元芬,王灵军,等.巨噬细胞迁移抑制因子调节寄生虫与宿主免疫系统相互作用机制的研究进展[J].中国血吸虫病防治杂志,2019,31(4):446-449. [28] WANG Z, XUE Y, WANG P, et al. MiR-608 inhibits the migration and invasion of glioma stem cells by targeting macrophage migration inhibitory factor. Oncol Rep. 2016;35(5):2733-2742. [29] LEE MC, MILLER EA, GOLDBERG J, et al. Bi-directional protein transport between the ER and Golgi. Annu Rev Cell Dev Biol. 2004;20:87-123. [30] FLIEGER O, ENGLING A, BUCALA R, et al. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett. 2003;551(1-3):78-86. [31] EICKHOFF R, JENNEMANN G, HOFFBAUER G, et al. Immunohistochemical detection of macrophage migration inhibitory factor in fetal and adult bovine epididymis: release by the apocrine secretion mode? Cells Tissues Organs. 2006; 182(1):22-31. [32] ROTH S, AGTHE M, EICKHOFF S, et al. Secondary necrotic neutrophils release interleukin-16C and macrophage migration inhibitory factor from stores in the cytosol. Cell death Discov. 2015;1(1):1-9. [33] DUMITRU CA, GHOLAMAN H, TRELLAKIS S, et al. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer. 2011;129(4):859-869. [34] NISHINO T, BERNHAGEN J, SHIIKI H, et al. Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med. 1995;1(7):781-788. [35] COSTA-SILVA B, AIELLO NM, OCEAN AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816-826. [36] TALUKDAR S, DAS SK, EMDAD L, et al. Autophagy and senescence: Insights from normal and cancer stem cells. Adv Cancer Res. 2021;150:147-208. [37] ZAKRZEWSKI W, DOBRZYŃSKI M, SZYMONOWICZ M, et al. Stem cells: past, present, and future. Stem Cell Res Ther. 2019;10(1):68. [38] KOLIOS G, MOODLEY Y.Introduction to stem cells and regenerative medicine. Respiration. 2013;85(1):3-10. [39] SIMONS D, GRIEB G, HRISTOV M, et al. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med. 2011;15(3):668-678. [40] BANK LM, BIANCHI LM, EBISU F, et al. Macrophage migration inhibitory factor acts as a neurotrophin in the developing inner ear. Development. 2012;139(24):4666-4674. [41] KANZLER I, TUCHSCHEERER N, STEFFENS G, et al. Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis. Basic Res Cardiol. 2013;108(1):310. [42] XIA W, ZHANG F, XIE C, et al. Macrophage migration inhibitory factor confers resistance to senescence through CD74-dependent AMPK-FOXO3a signaling in mesenchymal stem cells. Stem Cell Res Ther. 2015;6(1):82. [43] FUKAYA R, OHTA S, YAGUCHI T, et al. MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53. Cancer Res. 2016;76(9):2813-2823. [44] OTVOS B, SILVER DJ, MULKEARNS-HUBERT EE, et al. Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion. Stem Cells. 2016;34(8): 2026-2039. [45] SMITH J, ZYOUD A, ALLEGRUCCI C. A case of identity: HOX genes in normal and cancer stem cells. Cancers. 2019;11(4):512. [46] KUŞOĞLU A, BIRAY AVCı Ç. Cancer stem cells: a brief review of the current status. Gene. 2019;681:80-85. [47] CLARA JA, MONGE C, YANG Y, et al. Targeting signalling pathways and the immune microenvironment of cancer stem cells -a clinical update. Nat Rev Clin Oncol. 2020;17(4):204-232. [48] SIVANDZADE F, CUCULLO L. Regenerative stem cell therapy for neurodegenerative diseases: an overview. Int J Mol Sci. 2021;22(4):2153. [49] PENTICUFF JC, WOOLBRIGHT BL, SIELECKI TM, et al. MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential. Nat Rev Urol. 2019;16(5):318-328. [50] ALBAN TJ, BAYIK D, OTVOS B, et al. Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression. Front Immunol. 2020;11:1191. [51] SAKAMOTO D, TAKAGI T, FUJITA M, et al. Basic gene expression characteristics of glioma stem cells and human glioblastoma. Anticancer Res. 2019;39(2):597-607. [52] SOHN HM, KIM B, PARK M, et al. Effect of CD133 overexpression on bone metastasis in prostate cancer cell line LNCaP. Oncol Lett. 2019;18(2):1189-1198. [53] MAMOORI A, WAHAB R, VIDER J, et al. The tumour suppressor effects and regulation of cancer stem cells by macrophage migration inhibitory factor targeted miR-451 in colon cancer. Gene. 2019;697:165-174. [54] GAO SW, LIU F. Novel insights into cell cycle regulation of cell fate determination. J Zhejiang Univ Sci B. 2019;20(6):467-475. [55] YAMANAKA S. Pluripotent stem cell-based cell therapy-promise and challenges. Cell Stem Cell. 2020;27(4):523-531. [56] RAMAMURTHY P, WHITE JB, YULL PARK J, et al. Concomitant differentiation of a population of mouse embryonic stem cells into neuron-like cells and schwann cell-like cells in a slow-flow microfluidic device. Dev Dyn. 2017;246(1):7-27. [57] SARKAR SA, SHARMA RP. Expression of selected apoptosis related genes, MIF, IGIF and TNF alpha, during retinoic acid-induced neural differentiation in murine embryonic stem cells. Cell Struct Funct. 2002;27(2):99-107. [58] WANG X, CHEN T, LENG L, et al. MIF produced by bone marrow-derived macrophages contributes to teratoma progression after embryonic stem cell transplantation. Cancer Res. 2012;72(11):2867-2878. [59] FERRARO F, CELSO CL, SCADDEN D. Adult stem cels and their niches. Adv Exp Med Biol. 2010;695:155-168. [60] LIU D, PAVATHUPARAMBIL ABDUL MANAPH N, AL-HAWWAS M, et al. Coating materials for neural stem/progenitor cell culture and differentiation. Stem Cells Dev. 2020;29(8):463-474. [61] ZHANG X, CHEN L, WANG Y, et al. Macrophage migration inhibitory factor promotes proliferation and neuronal differentiation of neural stem/precursor cells through Wnt/β-catenin signal pathway. Int J Biol Sci. 2013;9(10):1108-1120. [62] OHTA S, MISAWA A, LEFEBVRE V, et al. Sox6 up-regulation by macrophage migration inhibitory factor promotes survival and maintenance of mouse neural stem/progenitor cells. PLoS One. 2013;8(9):e74315. [63] OHTA S, YAGUCHI T, OKUNO H, et al. CHD7 promotes proliferation of neural stem cells mediated by MIF. Mol Brain. 2016;9(1):96. [64] ZHAO F, XING Y, JIANG P, et al. LncRNA MEG3 inhibits the proliferation of neural stem cells after ischemic stroke via the miR-493-5P/MIF axis. Biochem Biophys Res Commun. 2021;568:186-192. [65] TORALDO DM, TORALDO S, CONTE L. The clinical use of stem cell research in chronic obstructive pulmonary disease: a critical analysis of current policies. J Clin Med Res. 2018;10(9):671-678. [66] VASANTHAN J, GURUSAMY N, RAJASINGH S, et al. Role of human mesenchymal stem cells in regenerative therapy. Cells. 2020. doi:10.3390/cells10010054. [67] KULUBYA ES, CLARK K, HAO DK, et al. The unique properties of placental mesenchymal stromal cells: a novel source of therapy for congenital and acquired spinal cord injury. Cells. 2021;10(11):2837. [68] XIA W, HOU M. Macrophage migration inhibitory factor rescues mesenchymal stem cells from doxorubicin-induced senescence though the PI3K-Akt signaling pathway. Int J Mol Med. 2018;41(2):1127-1137. [69] ZHANG Y, ZHU W, HE H, et al. Macrophage migration inhibitory factor rejuvenates aged human mesenchymal stem cells and improves myocardial repair. Aging (Albany NY). 2019;11(24):12641-12660. [70] PALUMBO S, TSAI TL, LI WJ. Macrophage migration inhibitory factor regulates AKT signaling in hypoxic culture to modulate senescence of human mesenchymal stem cells. Stem Cells Dev. 2014;23(8):852-865. [71] LOU SY, DUAN YT, NIE HZ, et al. Mesenchymal stem cells: biological characteristics and application in disease therapy. Biochimie. 2021;185:9-21. [72] BARRILLEAUX BL, FISCHER-VALUCK BW, GILLIAM JK, et al. Activation of CD74 inhibits migration of human mesenchymal stem cells. In Vitro Cell Dev Biol Anim. 2010;46(6):566-572. [73] FISCHER-VALUCK BW, BARRILLEAUX BL, PHINNEY DG, et al. Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency. Biotechnol Lett. 2010;32(1): 19-27. [74] XIONG CJ, HUANG B, ZHOU Y, et al. Macrophage migration inhibitory factor inhibits the migration of cartilage end plate-derived stem cells by reacting with CD74. PLoS One. 2012;7(8):e43984. [75] LOURENCO S, TEIXEIRA VH, KALBER T, et al. Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J Immunol. 2015;194(7):3463-3474. [76] ZHU W, SUN L, ZHAO P, et al. Macrophage migration inhibitory factor facilitates the therapeutic efficacy of mesenchymal stem cells derived exosomes in acute myocardial infarction through upregulating miR-133a-3p. J Nanobiotechnol. 2021;19(1):61. [77] CHEN H, XIA W, HOU M. LncRNA-NEAT1 from the competing endogenous RNA network promotes cardioprotective efficacy of mesenchymal stem cell-derived exosomes induced by macrophage migration inhibitory factor via the miR-142-3p/FOXO1 signaling pathway. Stem Cell Res Ther. 2020;11(1):31. [78] PETERS EB. Endothelial progenitor cells for the vascularization of engineered tissues. Tissue Eng Part B Rev. 2018;24(1):1-24. [79] PERROTTA F, PERNA A, KOMICI K, et al. The state of art of regenerative therapy in cardiovascular ischemic disease: biology, signaling pathways, and epigenetics of endothelial progenitor cells. Cells. 2020;9(8):1886. [80] KOU F, ZHU C, WAN H, et al. Endothelial progenitor cells as the target for cardiovascular disease prediction, personalized prevention, and treatments: progressing beyond the state-of-the-art. EPMA J. 2020;11(4):629-643. [81] EMONTZPOHL C, SIMONS D, KRAEMER S, et al. Isolation of endothelial progenitor cells from healthy volunteers and their migratory potential influenced by serum samples after cardiac surgery. J Vis Exp. 2017;(120):e55192. [82] EMONTZPOHL C, GOETZENICH A, SIMONS D, et al. Key role of MIF in the migration of endothelial progenitor cells in patients during cardiac surgery. Int J Cardiol. 2015;181:284-287. [83] GRIEB G, PIATKOWSKI A, SIMONS D, et al. Macrophage migration inhibitory factor is a potential inducer of endothelial progenitor cell mobilization after flap operation. Surgery. 2012;151(2):268-277.e261. [84] WANG J, LIN J, KAISER U, et al. Absence of macrophage migration inhibitory factor reduces proliferative retinopathy in a mouse model. Acta Diabetol. 2017; 54(4):383-392. [85] HU L, ZHAO B, WANG S. Stem-cell therapy advances in China. Hum Gene Ther. 2018;29(2):188-196. |
[1] | 孙可欣, 曾今实, 李佳, 蒋海越, 刘霞. 力学刺激提高生物3D打印软骨构建物基质的形成[J]. 中国组织工程研究, 2023, 27(在线): 1-7. |
[2] | 党 祎, 杜成砚, 姚红林, 袁能华, 曹 金, 熊 山, 张顶梅, 王 信. 激素型骨坏死与氧化应激[J]. 中国组织工程研究, 2023, 27(9): 1469-1476. |
[3] | 徐星星, 文超举, 孟茂花, 王勤英, 陈镜桥, 董 强. 口腔种植中的碳纳米材料[J]. 中国组织工程研究, 2023, 27(7): 1062-1070. |
[4] | 杨怡天, 王 璐, 姚 蔚, 赵 彬. 生物支架与巨噬细胞在骨再生中的相互影响及应用[J]. 中国组织工程研究, 2023, 27(7): 1071-1079. |
[5] | 李 诚, 郑国爽, 蒯贤东, 于炜婷. 海藻酸盐支架修复关节软骨[J]. 中国组织工程研究, 2023, 27(7): 1080-1088. |
[6] | 史业弘, 王 成, 陈世玖. 小口径人工血管的早期血栓形成与预防[J]. 中国组织工程研究, 2023, 27(7): 1110-1116. |
[7] | 唐昊天, 廖荣东, 田 京. 压电材料修复骨缺损的应用及设计思路[J]. 中国组织工程研究, 2023, 27(7): 1117-1125. |
[8] | 许 言, 李 平, 赖春花, 朱培君, 杨 烁, 徐淑兰. 血管化骨再生中压电生物材料的应用[J]. 中国组织工程研究, 2023, 27(7): 1126-1132. |
[9] | 薛 婷, 张新日, 孔晓梅. 纳米材料多模态显像示踪技术在间充质干细胞治疗尘肺中的应用[J]. 中国组织工程研究, 2023, 27(7): 1133-1140. |
[10] | 李欣悦, 李熙恒, 毛天娇, 唐 亮, 李 江. 三维培养人牙周膜干细胞的形态、活性及成骨分化能力[J]. 中国组织工程研究, 2023, 27(6): 846-852. |
[11] | 李启程, 邓 进, 付小洋, 韩 娜. 骨髓间充质干细胞来源外泌体对成肌细胞缺氧状态的影响[J]. 中国组织工程研究, 2023, 27(6): 853-859. |
[12] | 王 敏, 尹秀山, 王盈熹, 张 妍, 赵 龙, 夏书月. 吸入骨髓间充质干细胞来源外泌体减轻慢性阻塞性肺疾病的炎性损伤[J]. 中国组织工程研究, 2023, 27(6): 827-834. |
[13] | 郝柳芳, 段红梅, 王子珏, 郝 飞, 郝 鹏, 赵 文, 高钰丹, 杨朝阳, 李晓光. 转基因小鼠脊髓损伤后室管膜细胞的时空动态变化[J]. 中国组织工程研究, 2023, 27(6): 883-889. |
[14] | 李晓寅, 杨晓青, 陈淑莲, 李正超, 王梓琪, 宋 震, 朱达仁, 陈旭义. 胶原/丝素蛋白支架联合神经干细胞治疗创伤性脊髓损伤[J]. 中国组织工程研究, 2023, 27(6): 890-896. |
[15] | 黄贵江, 季雨伟, 赵 鑫, 杨 艺, 赵玉兰, 王佩锦, 唐 薇, 角建林. 胎盘间充质干细胞不同给药途径治疗骨质疏松性骨折树鼩的疗效和机制[J]. 中国组织工程研究, 2023, 27(6): 909-914. |
1.1 资料来源
1.1.1 检索人及检索时间 第一作者在2021年10月进行检索。
1.1.2 检索文献时限 重点检索时间范围为2010年1月至2021年10月,同时纳入少量远期经典文献。
1.1.3 检索数据库 PubMed和中国知网数据库。
1.1.4 检索词 英文检索词为“macrophage migration inhibitory factor,cancer stem cell,embryonic stem cell,neural stem cell,mesenchymal stem cell,endothelial progenitor cell,stem cell therapy,Organizational engineering”,中文检索词为“巨噬细胞迁移抑制因子、肿瘤干细胞、胚胎干细胞、神经干细胞、间充质干细胞、内皮祖细胞、干细胞治疗、组织工程”。
1.1.5 检索文献类型 研究性论文及综述性论文。
1.1.6 手工检索情况 无。
1.1.7 检索策略 PubMed和中国知网数据库文献检索策略,见图1。
1.1.8 检索文献量 初检文献量253篇。
1.2 入组标准
文题释义:#br# 巨噬细胞迁移抑制因子:是由多种细胞类型产生的一种多功能细胞因子,影响多种生物过程的调节功能,如增殖、迁移、凋亡和细胞周期进程。#br# 干细胞治疗:是把健康的干细胞移植到患者体内,以修复或替换受损细胞或组织,从而达到治愈的目的。#br# 中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
干细胞是一种可以自我更新并且具有分化潜能的细胞。由于上述特性,干细胞可以修复、替换或再生细胞、组织或器官,从而修复任何原因造成的受损功能,包括先天性缺陷、疾病、创伤和衰老[1]。许多干细胞正在研究并应用于治疗神经退行性疾病、血液病、心脏病和其他疾病[2-4]。在过去十年中,基于干细胞的再生医学已经发展到临床试验和治疗应用[5]。因此,干细胞治疗是一种很有前景的治疗方法。尽管如此,干细胞治疗的实验研究以及临床应用还存在一系列的问题。组织工程是将特定类型的细胞或细胞产物传送到受损组织或器官以恢复组织和器官功能[6]。干细胞的研究是组织工程的基础。干细胞关键特征、自我更新和分化特性受到多种信号通路、翻译因子和表观遗传变化等不同机制的严格控制。因此,深入了解干细胞的生长发育机制对于干细胞治疗以及组织工程意义重大。
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||